Results 191 to 200 of about 508,438 (349)

Localized NF‐κB Inhibition Reduces Lipid Nanoparticle‐Associated Inflammation

open access: yesAdvanced Science, EarlyView.
Lipid nanoparticles (LNPs) activate NF‐κB and provoke inflammation that limits therapeutic delivery. By encapsulating selective NF‐κB inhibitors within LNPs, localized suppression of inflammatory signaling is achieved without compromising mRNA expression.
Carolann L. Espy   +16 more
wiley   +1 more source

Adenoviral delivery of DNA plasmid for RNA silencing: pros and cons. [PDF]

open access: yesAnn Transl Med, 2023
Mokhtari-Esbuie F   +3 more
europepmc   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

open access: yesAdvanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason   +12 more
wiley   +1 more source

Lentivirus-based RNA Silencing of Nemo-like Kinase (NLK) Inhibits the CAL 27 Human Adenosquamos Carcinoma Cells Proliferation and Blocks G0/G1 Phase to S Phase [PDF]

open access: gold, 2013
Bin Zhang   +13 more
openalex   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

open access: yesAdvanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li   +6 more
wiley   +1 more source

Using real-time qPCR to evaluate RNAi-mediated gene silencing [PDF]

open access: yes, 2009
De Clercq, S   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy